UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337
UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.
Stocks · News reference
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-09-15 AccNo: 0001628280-26-061978 Size: 346 KB Item 7.01: Regulation FD Disclosure
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.
Jazz Pharmaceuticals shares are trading higher after the company announced second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial.